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Myalgic encephalomyelitis (Me), also known as Chronic Fatigue syndrome (CFs) is a debilitating 
condition. there is growing interest in a possible etiologic or pathogenic role of mitochondrial 
dysfunction and mitochondrial DNA (mtDNA) variation in Me/CFs. supporting such a link, fatigue is 
common and often severe in patients with mitochondrial disease. We investigate the role of mtDNA 
variation in Me/CFs. No proven pathogenic mtDNA mutations were found. We then investigated 




Myalgic encephalomyelitis (ME), also known as chronic fatigue syndrome (CFS) is an illness characterized by 
post-exertional malaise, cognitive dysfunction, unrefreshing sleep, and other symptoms1. Severe fatigue is the 
defining clinical problem, and sleep or rest does not alleviate this fatigue. ME/CFS is a disease associated with 
substantial levels of disability in many patients, with a high social and economic cost2. Skeletal muscle fatigue, and 
more specifically post-exertional malaise, is a key feature of ME/CFS, and recent studies point to abnormalities 
of muscle function3. Patients suffering from ME/CFS show a reduced capacity to recover from acidosis on repeat 
exercise3,4, which is suggestive of a role for mitochondrial dysfunction in the pathophysiology of this disease. In 
vitro investigations have supported this hypothesis with studies showing functional mitochondrial abnormalities 
such as a lower mitochondrial respiratory function in ME/CFS patients5.
ME/CFS is clinically heterogeneous with the patients most severely affected being house- or even bed-bound 
for months and sometimes years. Recent findings have indicated that the house-bound group represents one 
quarter of the patient population2. The functional abilities of these patients are significantly more impaired in 
many aspects compared to ME/CFS patients who were not house-bound, including but not limited to fatigue, 
post-exertional malaise, sleep and pain, as well as neurocognitive, autonomic, neuroendocrine, and immune 
functioning2. However, the factors that make a patient less or more likely to fall into this severely affected group 
are unknown, as are the factors linked to recovery. Evidence suggests that recovery remains rare in the ME/CFS 
patient population regardless of disease severity6.
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Clinically proven pathogenic mtDNA mutations are recognized as a cause of maternally-inherited disorders, 
with a minimum prevalence rate of 1 mutation in 5,000 (20 per 100,000) people7. Such mtDNA mutations fre-
quently cause multisystem disorders with fatigue being prevalent in these patient groups8. Hundreds or even 
thousand of copies of mtDNA are present in a /cell, this is linked to the energetic demands of the cell. These copies 
can either be identical, a state called homoplasmy, or two or more species of mtDNA can be present in a state 
referred to as heteroplasmy. Thus, a possible approach is to investigate whether mtDNA mutations are present 
either at heteroplasmy levels sufficient to cause mtDNA disease or at sub-clinical levels that are too low to cause 
primary mtDNA disease, but are perhaps at sufficient levels to act as a risk factor or affect the course of a complex 
disease such as ME/CFS.
Beyond such recognised pathogenic mtDNA mutations, many studies have suggested a role for common 
mtDNA variants in complex diseases, with mtDNA variants either modulating susceptibility to a disease and/
or affecting the course of the disease, including those where fatigue is an important feature of disease9,10. While 
many studies have reported a significant association of specific mtDNA haplogroups with a number of complex 
disorders, there is often substantial disagreement among different studies examining the same phenotype.
Another possibility is that rare mtDNA population variants might have a role in the disease process, since rare 
variants are predicted to be more mildly deleterious as such variants are removed by purifying selection over gen-
erations11. This is supported by recent works12,13, using a computational tool, MutPred, that has been widely used 
in the mitochondrial context14. Given this it might be expected to see a greater number of rare/mildly deleterious 
variants in any given patient group15, which may implicate a role in the disease process.
In addition to acting as a susceptibility factor to disease, it has also been suggested that mtDNA variants 
might modify the course of common complex diseases16. In line with this a recent study of 193 ME/CFS patients 
and 196 age- and gender-matched controls, reported haplogroups J, U and H, as well as eight mtDNA SNPs are 
significantly associated with particular ME/CFS symptoms in patients (course of disease), but not with increased 
susceptibility to ME/CFS (onset of disease)10.
In the current study, using mtDNA sequence data from ME/CFS patients from both the United Kingdom 
(UK) and South Africa (RSA), we ask whether mtDNA population variants alter susceptibility to ME/CFS. Due 
to the maternal inheritance pattern of mtDNA, linking mtDNA variation to common complex traits has been 
recognized as a difficult task, with models used in nuclear association genetics proving unsuitable17,18. There have 
been a number of improvements in the design of haplogroup association studies over the last 10 years, such as 
the importance of a replicate cohort being recognized15,19. However, there are still many doubts as to whether this 
simple methodology is the correct approach to assess the role of mtDNA variation in complex disorders. Indeed, 
a number of prior studies have applied the haplogroup association approach in complex diseases where fatigue 
is an important clinical feature, such as multiple sclerosis9,20, but the results were inconclusive. Here, we applied 
an improved approach which focuses on variants predicted computationally to be mildly deleterious, most of 
which are rare. This approach takes advantage of the advances in bioinformatics21,22 using the mtDNA-server23 
and MutPred tools14,23.
Results
Heteroplasmy analysis. To investigate the possibility that ME/CFS patients harbour clinically proven 
mtDNA mutations, either above the threshold required for mtDNA disease or at a sub-threshold level, the com-
plete mitochondrial genomes of the (n = 89 moderate; 29 severely affected) patients from the UK and (n = 143) 
South African ME/CFS patients were analysed. Only two mutations associated with clinically proven mitochon-
drial disease were seen, m.3337G>A24 in a patient and m.11778G>A25 in a control participant, both in the South 
African cohort. However, these mutations were heteroplasmic at the 5% and 16.5% level respectively, and as a 
result these mutations are unlikely to have a phenotypic role. No other clinically proven mtDNA mutations were 
detected in any of the patient or control groups. It should be noted that such frequencies of low level pathogenic 
mtDNA mutations are entirely consistent with large population studies considering this question26, as well as 
prior studies on this phenotype10,27.
Haplogroup distributions. Human mtDNAs can be assigned to one of several haplogroups. This tradi-
tional classification system was originally based on the presence or absence of one or a small number of likely 
benign polymorphisms28, rather than mutations with functional consequences. However, the advent of large-scale 
sequencing has led to the identification of a vast number of haplogroup-specific polymorphisms, allowing hap-
logroup classifications to be expanded into more and more subgroups29. To put our analysis into the context of 
prior studies, a simple haplogroup distribution analysis was performed.
To ensure a robust comparison between the groups from the UK and the RSA, only the frequencies of the nine 
haplogroups of European origin (HVUKTJIXW) from the RSA ME/CFS cohort were used, as the group from 
the UK (North East England) was of lower diversity. The haplogroup distributions for the UK and RSA cohorts 
– ME/CFS and control - are given in Table 1. Comparing the haplogroup distributions between the UK ME/CFS 
patients and controls with a Monte Carlo-based approach, no significant difference was observed (ns, p = 0.31). 
Similarly, there was no significant difference in haplogroup distribution between RSA patients and controls (ns, 
p = 0.55). Thus as in the work of Billing-Ross et al., mtDNA haplogroup was not seen to affect the susceptibility 
to ME/CFS10.
Network analysis. Functional networks were produced for the UK cohort (Fig. 1a) and the RSA cohort 
(Fig. 1a). These networks represent all possible least complex phylogenetics trees, based on the variants included 
as described in Methods. Sequences that are very similar cluster together in smaller or larger nodes. Nodes are 
ordered along a phylogenetic tree with links indicating the variants by which a connected node deviated from 
another30. In both cohorts, controls were more abundant in nodes that were separated by several variants from 
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Haplogroups
Number of persons assigned to each haplogroup per group (% in brackets)
UK RSA
ME/CFS severe ME/CFS patients Controls ME/CFS patients Controls
(N = 29) (N = 89) (N = 64) (N = 143) (N = 98)
HV 14 (48) 41 (46) 22 (34) 66 (34) 37 (38)
I — 3 (3) 2 (3) 1 (0.5) 1 (1)
J 5 (17) 12 (14) 13 (20) 15 (8) 11 (11)
K 1 (3) 5 (6) 9 (14) 12 (6) 8 (8)
R — — — 1 (0.5) 5 (5)
T 3 (10) 11 (12) 5 (8) 13 (7) 14 (14)
U 5 (17) 13 (15) 11 (17) 32 (17) 20 (20)
W — 2 (2) 1 (2) 1 (0.5) 2 (2)
X 1 (3) — 1 (2) 2 (1) —
Table 1. Haplogroup distribution for each group in the two cohorts. UK: United Kingdom; RSA: Republic of 
South Africa; ME/CFS: Myalgic encephalomyelitis/chronic fatigue syndrome.
Figure 1. Shows functional networks of UK participants (a) and RSA (a) participants. Ellipses indicate clusters 
of branches and nodes that fall within similar haplogroups. Small red nodes indicate potential median vectors. 
Pie-chart nodes indicate the proportion of individuals per phenotype classification, as well as the number of 
participants per node. mtDNA variants responsible for links are listed. Transversions are shown in italics.
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the central, haplogroup H-dominated nodes. These peripheral nodes frequently contained mtDNAs that could 
be assigned to haplogroups T, K and U, although as noted in the previous section, no significant haplogroup 
associations were found.
Individuals with a potentially mildly deleterious mtDNA variant. Haplogroup association studies 
are confounded by a number of factors, including population stratification, with this and other factors resulting in 
elevated type 1 error18,31. These limitations, coupled with the relatively low statistical power of haplogroup associ-
ation studies32, underscore the fact that new methods are required for discerning the pathogenic and/or etiologi-
cal role of mtDNA mutations in a common complex disorder21,22. We determined the number of individuals with 
mtDNA sequences containing a variant with a MutPred score over the 0.5 threshold, such variants being consid-
ered “actionable hypothesis” or candidates for having a functional effect14, here referred to as “mildly deleterious”.
The number of controls and patients in each population that harbours none, one or more mildly deleterious 
variants are summarised in Table 2. Figure 2 illustrates these numbers as percentages of each group.
For the cohorts collected in the North East of England, 49 (55%) of the moderate ME/CFS patients were with-
out a mildly deleterious variant. Comparing this result to the controls from the United Kingdom, only 17 (27%) 
of these individuals had no such variants. Conversely 45% of moderate ME/CFS patients had one or more mildly 
deleterious variants, compared to 72% of controls from the UK who harboured one or more such variants (see 
Fig. 2). These differences were found to be highly significant (p = 0.0008) with a Fisher’s Exact test. This obser-
vation suggests that individuals with ME/CFS are less likely to have an mtDNA variant that is predicted to have a 
functional impact.
As mentioned above, as many as 25% of those with ME/CFS are severely affected, being house or even bed 
bound. A cohort of such patients was recruited in the North East of England (UK). Of the 29 severe ME/CFS 
patients 15 (52%) were without a mildly deleterious variant. Comparing these numbers with those of UK controls 
using a Fisher’s Exact test, a significant difference (p = 0.03) was found. Thus even the most severely affected 
patients had fewer mildly deleterious variants than the controls. It is important to note that when the moderately 
and severely affected patients are compared using a Fishers exact test no difference is observed (p = 0.83). 
The analysis was repeated in the RSA cohort, including only those ME/CFS cases that fall within the nine hap-
logroups designated as European (HVUKTJIXW) to ensure that differences in lineage diversity could not impact 
upon the results. Conducting the same analysis with the ME/CFS 143 patients from the RSA, there were 80 (56%) 
individuals with predicted mildly deleterious variants; considering the healthy controls from the RSA, 40 (41%) 
individuals had no such variants. That leaves 59% of controls from South Africa compared to only 44% of ME/
CFS patients who harbour one or more mildly deleterious mtDNA variants. A Fisher’s exact test again found these 
differences to be statistically significant (p = 0.03). Our analyses thus show, for both UK and RSA cohorts, those 
with ME/CFS have fewer mildly deleterious variants than controls.
Discussion
We have investigated a possible role of mtDNA variants in ME/CFS. This was done firstly by reviewing the 
sequence data of each individual for the presence of clinically proven pathogenic mtDNA mutations associated 
with primary mitochondrial disease. We ruled out the possibility that previously identified pathogenic mtDNA 
mutations are contributing to ME/CFS, a result that was not unexpected10,27.
Secondly, we considered the possible role of population variants in ME/CFS, with a focus on variants that are 
predicted to be mildly deleterious by computational methods. These variants are frequently rare at the population 
level resulting in an absence of population stratification, and thus in a lower chance of false association or type 1 
error. Such false associations are believed to be common in mtDNA association studies applying the haplogroup 
association model18. The current approach has been utilized in two prior studies21,22 that considered Alzheimer 
and cardiovascular disease respectively.
We compared the number of individuals in both the ME/CFS patient and control groups with variants classi-
fied as mildly deleterious, to the number of individuals without such variants. In both the UK and RSA cohorts, 
there was a significant difference between the patients and the controls, with the ME/CFS patients having a higher 
percentage of patients without a variant predicted to be mildly deleterious. Although surprising, this observation 
was seen in two independent cohorts, suggesting that these differences are not due to chance. One of the rea-
sons for this observation might have been that deleterious variants confer disease susceptibility in only severely 
affected ME/CFS patients or modulate fatigue severity among ME/CFS patients. However, when comparing 
Number of variants with 
MutPred scores above 0.5
Number of individuals harbouring variants with MutPred scores >0.5 (% in brackets)
UK RSA
Controls ME/CFS patients severe ME/CFS Controls ME/CFS patients
(N = 64) (N = 89) (N = 29) (N = 98) (N = 143)
0 17 (27) 49 (55) 15 (52) 40 (41) 80 (56)
1 18 (28) 8 (9) 2 (7) 10 (10) 28 (20)
2 18 (28) 19 (21) 9 (31) 29 (30) 28 (20)
3 7 (11) 12 (14) 3 (10) 18 (18) 7 (5)
4 3 (5) 1 (1) — 1 (1) —
Table 2. Number of individuals that harbour high MutPred scored variants. UK: United Kingdom; RSA: 
Republic of South Africa; ME/CFS: Myalgic encephalomyelitis/chronic fatigue syndrome.
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patients that were severely affected with controls in the UK cohort, again ME/CFS patients had fewer variants 
predicted to be mildly deleterious. Furthermore, there was no difference in the number of patients with such var-
iants between the moderate and severely affected groups. Taken together, these data suggest that our observation 
is not the result of a simple patient stratification effect, although additional replication cohorts of moderate and 
severely affected ME/CFS cohorts are needed to confirm this.
It has been proposed that those with ME/CFS might not have a problem with ATP production33, but rather 
with ATP utilization. Therefore, we consider this genetic difference in mtDNA variation as an accurate obser-
vation which may prove to have a biological relationship to the function and regulation of the OXPHOS system 
and subsequent wide-ranging immediate and downstream consequences on energy metabolism34,35. It should be 
considered that the wider homeostasis and/or responsiveness of the various elements of energy metabolism are 
affected in ME/CFS, rather than merely single “segments” of energy pathways such as ATP production.
A number of mitochondrial abnormalities in ME/CFS have previously been reported, indicating that mito-
chondrial dysfunction may play a role in the pathogenesis of disease, at least in a sub-set of patients36. Previously 
ME/CFS patients have been shown to have significantly lower mitochondrial function than healthy controls5. 
Detection of these mtDNA variants has the potential to be used as a tool for measuring mitochondrial dys-
function in ME/CFS. Another avenue of investigation in the mitochondrial field is copy number analysis. 
Mitochondrial DNA copy number (mtDNAcn) has been reported as an indirect representative of mitochondrial 
function and as a biomarker of disease with studies. As an example, in Parkinson’s disease (PD), mtDNAcn was 
elevated in the pedunculopontine nucleus (PPN), which is a brainstem region associated with progression of 
motor and non-motor symptoms of PD37. Other neurodegenerative conditions in which alterations in mtDNAcn 
have been reported include Multiple Sclerosis. The results in this phenotype are conflicting, with some showing 
evidence for reduced copy number38, while others indicate an increase39. Additionally. MtDNAcn was shown not 
to be associated with fatigue status in Primary Sjögren’s Syndrome30. Taken together these papers demonstrate 
that in heterogeneous diseases with a variable course small single time point studies will produce data that is 
difficult to interpret and is likely to conflict between studies.
Figure 2. Pie-charts indicating the percentage of controls and ME/CFS patients that harbour variants 
with MutPred scores above 0.5 for the (a) UK cohort and (b) South African cohort. ME/CFS: Myalgic 
encephalomyelitis/chronic fatigue syndrome.
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In conclusion, this is the first paper to demonstrate mitochondrial genetic differences between ME/CFS 
patients and controls. It also demonstrates the power of mtDNA analysis focused on variants likely to be of a func-
tional effect to detect differences between case and control cohorts where the traditional haplogroup association 
method frequently fails to do so. Future studies need to include larger cohorts from multiple centres, within and 
between nations, with standardized sample handling. These studies need to take a multi-disciplinary approach 
linking genetics, including mtDNA copy number analysis and bioenergetics. Given the changing nature of the 
disease, longitudinal studies would seem to be essential to further understanding by allowing us to determine 
how mtDNA varation and mitochondrial dysfunction relates to fluctuations in symptom severity.
Methods
ethical approval and informed consent. This study was conducted in two independent cohorts, one 
from England and the other from South Africa. All experimental protocols were approved by the corresponding 
intuitional committees, namely the CRN National Coordinating Centre (CRNCC) | NIHR Clinical Research 
Network (CRN) in England (UK ME/CFS - IRAS ID 221364) and the Health Research ethics committee (HREC) 
of the North-West University in South Africa (SABPA: NWU 00036-07-S6, CFS: NWU 00102-12). All study pro-
cedures carried out in accordance with relevant guidelines and regulations of Newcastle University and North-
West University. All participants gave informed consent and were over the age of 18.
patient cohorts. We used two well-characterised cohorts of ME/CFS patients, one from the North East of 
England (n = 89 moderately affected; 29 severely affected) and the other from South Africa (n = 143 moderately 
affected). Both cohorts met the Fukuda diagnostic criteria1. Potentially confounding causes of fatigue, including 
depression, were excluded in all patients. The two control cohorts were regionally matched and had been collected 
for two prior studies. The controls from the North East of England (n = 64) were used previously for a variant 
load study on Alzheimer’s disease15. The control cohort from South Africa (n = 98) was comprised of healthy high 
school teachers assembled previously for a study on hypertension and diabetes22.
sequencing. Sequencing of the ME/CFS samples from both the UK and RSA was carried out at Source 
Bioscience using a fluidigm technology. The sequencing methodology for the controls has been described previ-
ously for the UK controls15 and for the RSA controls22. The reference sequence used in all datasets was the revised 
Cambridge reference sequence (rCRS).
Network analysis. After selective pruning of the total mtDNA variants to those in (a) protein-encoding 
genes with MutPred pathogenicity scores above 0.5, and (b) rRNA and tRNA variants, a functional maximum 
parsimony (MP) network analysis was performed with the NETWORK (version 5.0.0.3) software package (http://
www.fluxus-engineering.com/sharenet.htm). Transversions, being chemically less likely to occur, were weighted 
three times more than transitions. Star contractions were performed using a maximum radius of 5. This step was 
followed by reduced median (RM)40 processing (reduction threshold r was 1). The “Frequency >1” criterion was 
activated to exclude sequences which are unique to the dataset. Network figures were produced using NETWORK 
Publisher (version 2.1.1.2), PowerPoint (Microsoft Office 365) and Adobe Photoshop Elements (version 10.0).
Data analyses. Sequencing data was processed using the online mtDNA-server (mtdna-server.uibk.ac.at)23 
tool. With this tool, homo- and heteroplasmy variants were identified. The pathogenicity status of heteroplasmic 
variants were assessed using various clinical and online databanks e.g. MitoMap, and the application of accepted 
scoring criteria41,42. For all other analyses described below, only homoplasmic variants and those with a hetero-
plasmy level above 90% were used, thus only inherited and not somatic variants were considered. Haplogroups 
were assigned using the online Haplogrep 2.0 tool (haplogrep.uibk.ac.at)43. The control data from the UK is 
Sanger Sequence data, the processing of which is described in44.
Classification and selection of mtDNA variants, as compared by group.  Analysis using variants 
predicted to be mildly deleterious are less prone to the effects of population stratification because they typically 
analyse rare variants that are not stratified between geographical locations. The variants are assessed using the 
MutPred program, which assigns a “pathogenicity” score between 0–1 (an amino acid change with 0 is predicted 
to be perfectly benign). A score above 0.5 for an amino acid change is classified as an “actionable hypothesis”14. 
Variants with pathogenicity scores below the “actionable hypothesis” threshold (0.5) are considered less likely 
to be deleterious or to have an impact on protein function; instead, they are more likely to be common pop-
ulation variants. The inclusion of these more numerous but low-scoring, low-impact variants in the analyses 
could be problematic, especially because the resultant “noise” differs greatly among different population groups45. 
Therefore, as in some of our previous studies, we have not included variants scoring below 0.5 in the current 
analyses22.
statistical analyses. All statistical analyses were performed using SPSS Statistics (Version 25), Prism 
(Version 23) or GraphPad (Version 7). Haplogroup distribution between ME/CFS patient cohorts and their cor-
responding control were performed using a Monte Carlo based approach, this methodology is part of the stand-
ard package but more accurate than the Chi Square estimation. Fisher’s exact tests were utilised to compare the 
number of patients and controls in each cohort that have mtDNA variants with MutPred scores above 0.5 (mildly 
deleterious) with those who do not.
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Data Availability
Whole mtDNA sequences for the South African controls have been deposited in the sequence read archive (SRA) 
of NCBI under BioProject accession number PRJNA403942 (https://www.ncbi.nlm.nih.gov/bioproject/403942). 
The UK controls can be found https://link.springer.com/article/10.1007%2Fs00439-005-0123-8 as electronic sup-
plemental material.
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